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Abstract
For many dose–response studies, large samples are not available. Particularly, when the outcome of interest is binary rather than
continuous, a large sample size is required to provide evidence for hormesis at low doses. In a small or moderate sample, we can
gain statistical power by the use of a parametric model. It is an efficient approach when it is correctly specified, but it can be
misleading otherwise. This research is motivated by the fact that data points at high experimental doses have too much contribution in the hypothesis testing when a parametric model is misspecified. In dose–response analyses, to account for model
uncertainty and to reduce the impact of model misspecification, averaging multiple models have been widely discussed in the
literature. In this article, we propose to average semiparametric models when we test for hormesis at low doses. We show
the different characteristics of averaging parametric models and averaging semiparametric models by simulation. We apply the
proposed method to real data, and we show that P values from averaged semiparametric models are more credible than P values
from averaged parametric methods. When the true dose–response relationship does not follow a parametric assumption, the
proposed method can be an alternative robust approach.
Keywords
hypothesis testing, hormesis, model misspecification, model averaging, Akaike information criterion

Introduction
In toxicology, hormesis is known to be a biphasic dose–
response relationship with a stimulatory response at low doses
and an inhibitory response at high doses.1,2 In this article, we
focus on statistical hypothesis testing for hormesis when the
outcome of interest is binary. The null hypothesis is the
absence of hormesis denoted by H0, and the alternative hypothesis is the presence of hormesis denoted by H1. For illustration,
2 models for H0 and 2 models for H1 are shown in Figure 1.
Mathematically speaking, we do not have a sign change in
the slope of a dose–response curve at low doses when H0 is
true. The slope is entirely positive at low doses (top left in the
figure), or the zero slope (ie, flat line) becomes a positive slope
after passing some threshold dose point (top right in the figure).
On the other hand, we have 1 sign change in the slope at low
doses when H1 is true. The starting slope is negative, and the
slope becomes positive at some dose point (bottom left and
bottom right in the figure). When H0 is true, for a given significance level a, we want the probability of rejecting H0 to be
at a or below. When H1 is true, we want the statistical power as
high as possible.

We can increase the statistical power by increasing the
number of experimental doses and/or the sample size inside
the hormetic range. In such a case, various statistical methods
are available including polynomial, fractional polynomial
modeling, splines, and nonparametric smoothing techniques.3
However, having such an ideal experimental design is not
always possible in practice. Although we prefer statistical
methods that require weak assumptions, we need to borrow
a parametric assumption to gain statistical power in smallsample studies. Several useful parametric models used in
dose–response assessments are equipped in Benchmark Dose
Model software.4 These models can be modified to quadratic
or other alternative forms in order to model a nonmonotonic
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Figure 1. Dose–response relationships. The top figures show 2
hypothetical monotonic dose–response relationships (null hypothesis,
denoted by H0), and the bottom figures show 2 hypothetical hormetic
dose–response relationships (alternative hypothesis, denoted by H1).

dose–response relationship.5-7 A parametric model yields a
high statistical power when it is correctly specified, but it can
lead to a very low statistical power when it is misspecified.
The loss of statistical power due to model misspecification
will be shown in this study. There are 2 main reasons. First,
the observed data points cannot be adequately modeled by
the parametric structure.3 Second, in the case of model misspecification, data points at high doses make situations even
worse because they have too much contribution in the parameter estimation. Such data points are called high-leverage
points.8
We have 2 aims in this article. First, we explicitly address
the impact of model misspecification and high-leverage
points in parametric modeling when we perform hypothesis
testing for hormesis at significance level a. Second, we propose averaging multiple semiparametric models using the
weights calculated by Akaike information criterion (AIC).9
In both frequentist and Bayesian frameworks, model averaging methods have been widely discussed in cancer risk
assessments, particularly for the estimation of benchmark
dose. Model averaging allows us to reduce the impact of
model misspecification and to account for model uncertainty.7,10-13 In this article, we present the simulation study
to compare parametric methods and the proposed semiparametric method. For illustration, we apply the methods to some
data discussed in Calabrese and Baldwin14 which seem to
show evidence for hormesis at various degrees. In the application, we show that P values calculated from parametric
models can be misleading, and P values calculated from the

In this section, we review a logistic regression model in
“Logistic Regression Model” subsection We base our discussion on the logistic model among many parametric models
because of its popularity, and the same discussion can be carried out for another form of parameterization. We briefly
review the model averaging method based on the AIC in
“Model Averaging in Parametric Models (L3 and L4)” subsection. We then discuss the application of model averaging to
semiparametric models in “Application of Model Averaging to
Semiparametric Models” subsection. More mathematical detail
is included in the Appendix.
The following notation is used in the section. Let xj  0
denote the jth fixed experimental dose for j ¼ 1, . . . , J, where J
is the total number of experimental doses. Without loss of
generality, let x1 ¼ 0 be the control dose and x1 < x2 < . . . <
xJ. Let Yij denote the binary random variable, where Yij ¼ 1 if
the ith experimental unit treated at dose xj shows a toxic outcome and Yij ¼ 0 otherwise. Let pj denote the unknown probability of observing Yij ¼ 1 (ie, the probability of observing a
toxic outcome at does xj). Let nj denote the number of experimental units observed at dose xj, and let N ¼ Sj nj denote the
total sample size for the experiment.

Logistic Regression Model
To model a potential “J-shaped” dose–response relationship, a
logistic regression model with the quadratic term


pj
log
¼ b0 þ b1 xj þ b2 x2j
1  pj
is briefly discussed by May and Bigelow.3 They considered the
log dose, but it is not an important distinction in our discussion.
Throughout the article, the logistic regression model is referred
to as the L3 model, where L3 stands for the logistic regression
model with 3 parameters b0, b1, and b2. The quadratic term
allows a hormetic dose–response curve at low doses, and similar parameterizations are discussed by Bogen6 and Kim et al7
using different link functions. In the quadratic form, hypothesis
testing for hormesis is simply formulated as H0: b1  0 versus
H1: b1 < 0. In a large sample, we can make inference for b1
based on the maximum likelihood estimator for b1, but we
usually do not observe such a large sample size particularly
inside the hormetic range in practice.3 In this article, we base
our inference on bootstrapping to approximate the sampling
distribution of the maximum likelihood estimator for b1.15 Our
focus is on the consequence of wrong implementation of this
model.
The L3 model is an efficient statistical strategy when it is
correctly specified. On the other hand, when the model is misspecified, it can lead us to a misleading result even in a large
sample. Under model misspecification, observations made at

Kim and Sanders

3

Hormetic Zone
Dose

Long Asymmetric Hormetic Zone

Probability

Short Asymmetric Hormetic Zone

Probability

Probability

Symmetric Hormetic Zone

Hormetic
Zone

Hormetic Zone
Dose

Dose

Figure 2. Hormetic dose–response relationships generated by the logistic regression models. The left figure is the L3 model with b0 ¼ 1.5, b1
¼ 5, and b2 ¼ 10, the middle figure is the L4 model with b0 ¼ 1.5, b1 ¼ 5, b2 ¼ 10, and b3 ¼ 0.5, and the right figure is the L4 model with b0
¼ 1.5, b1 ¼ 5, b2 ¼ 10, and b3 ¼ 2.

high experimental doses have too much contribution in the
estimation of b1 (known as high-leverage points), and it can
significantly decrease statistical power. Motivated by a power
transformation described by Tukey transformation,16 the L3
model can be modified as


pj
log
¼ b0 þ b1 ðxj Þb3 þ b2 ðx2j Þb3
1  pj
where b3 > 0. This parameterization is referred to as the L4
model, where L4 stands for the logistic regression with 4 parameters b0, b1, b2, and b3. A similar parameterization was discussed by Kim et al.17 Compared to the L3 model, the L4
model is more flexible while it maintains the same form of
hypothesis testing H0: b1  0 versus H1: b1 < 0. As shown in
Figure 2, the L3 model is limited to a symmetric hormetic zone
only (figure on the left), and the L4 model is able to generate an
asymmetric hormetic zone by adding the power parameter b3
(figures in the middle and on the right). Note that the L3 model
is a special case of the L4 model when b3 ¼ 1.

Model Averaging in Parametric Models (L3 and L4)
The advantage of the L3 model is efficiency (high statistical
power) when the true hormetic zone is symmetric and the true
dose–response relationship follows the quadratic form. The
disadvantage is a loss of statistical power when the model is
misspecified. It is also sensitive to high-leverage points. The
impact of model misspecification and high-leverage points can
be increased particularly when the experiment is poorly
designed. On the other hand, the advantage of the L4 model
is flexibility, and it can maintain relatively high statistical
power when the true hormetic zone is asymmetric. The disadvantage of L4 is a loss of statistical power due to overparameterization when the true hormetic dose–response relationship
can be adequately modeled by the L3 model. To compromise
the characteristics of L3 and L4, we may consider the model
averaging method based on the AIC.9 The method of AIC

model averaging is often used to account for model uncertainty
and to reduce the impact of model misspecification when a
single model is used for inference.10,18,19
Let wL3 and wL4 denote the AIC weight calculated from the
observed data, where wL3 þ wL3 ¼ 1 (see Appendix). When a
fitted model has a higher value of the likelihood function than
the other fitted model, it receives a higher weight. In addition, it
penalizes an additional model parameter to balance between
goodness of fit and overparameterization. When we have 2
bootstrap distributions from L3 and L4, we can consider a
mixture distribution according the AIC weights. Since both
L3 and L4 determine hormesis by the sign of b1, we can perform the hypothesis testing H0: b1  0 versus H1: b1 < 0 based
on the mixture distribution of estimated b1. At significance
level a ¼ .05, we reject H0 in favor of H1 when the (1 
a)th quantile of the distribution is below 0. Throughout the
discussion, this model averaging method is referred to as MAP
(model averaging with the parameter models). When H0 is true,
the type I error rate under MAA is fairly close to the minimum
of the type I error rate under L3 and the type I error rate under
L4 (see Appendix and Simulation Result).
Averaging b1 in L3 and b1 in L4 is a meaningless procedure
when our goal is parameter estimation. However, our goal is
hypothesis testing not parameter estimation. Though b1 in L3
and b1 in L4 have different meanings, both b1 < 0 in L3 and b1 <
0 in L4 have the same meaning (presence of hormesis) in the
context of our hypothesis testing. Under each model using bootstrapping, we may seek evidence for b1 < 0 through the bootstrap
distribution of estimated b1. Therefore, when a mixture bootstrap distribution of estimated b1 is mostly negative (regardless
of magnitude), it may be regarded as evidence for hormesis.

Application of Model Averaging to Semiparametric
Models
Recall that we let pj denote the probability of a toxic outcome
at dose xj. In general, we need evidence for p1 > p2 to reject H0

4
in favor of H1. In this section, we introduce a proposed model
averaging method which does not require a link function
between the probability of a toxic outcome and the dose.
Let M1 denote the saturated model with J free parameters,
p1, p2, . . . , pJ, so each pj is estimated by the observed proportion at dose xj. Let M2 denote a model with J  1 free parameters by the condition p2 ¼ p3, so p2 is estimated by the
observed proportion at the 2 doses x2 and x3. Let M3 denote a
model with J  2 free parameters by the condition p2 ¼ p3 ¼
p4, so p2 is estimated by the observed proportion at the 3 doses
x2, x3, and x4. Using general notation, let Mk denote the model
with J  k þ 1 free parameters such that p2 ¼ . . . ¼ pkþ1. We
consider up to MJ2 and obtain the AIC-weights w1, . . . , wJ2
by maximizing the log-likelihood function (see Appendix for
detail). When we have more experimental units inside the hormetic range, the model averaging will become more robust
regardless of the values of x1, . . . , xJ because the model structure depends on the order x1, . . . , xJ and estimated p1, . . . , pJ. It
does not assume a particular shape of dose–response curve.
For each Mk, we can obtain the bootstrap distribution of
estimated p1  p2, then we test for hypothesis testing H0:
p1  p2  0 versus H1: p1  p2 > 0 based on the mixture of
the J  2 bootstrap distributions weighted by the AIC weights.
At significance level a, we reject H0 in favor of H1 when the
ath quantile of the mixture distribution exceeds 0. Throughout
the discussion, this model averaging method is referred to as
MASP (model averaging with semiparametric models).

Results
In this section, we compare the operating characteristics of the
4 aforementioned models: L3, L4, MAP, and MASP. We consider 16 simulation scenarios with 5 scenarios under H0 and 11
scenarios under H1 (see Simulation Design). We summarize the
simulation results by the probability of rejecting H0 under each
scenario and for each model (see Simulation Result). Then, we
apply the 4 models to the data discussed in Calabrese and
Baldwin14 which provided some degree of evidence for hormesis at low doses (see Application).

Simulation Design
To control noise in the simulation, for all 16 scenarios, we
assumed J ¼ 6 experimental doses geometrically spaced as
x1 ¼ 0, x2 ¼ 0.0625, x3 ¼ 0.125, x4 ¼ 0.25, x5 ¼ 0.5, and x6
¼ 1, and we assumed nj ¼ 50 for each dose group so that N ¼
300 is the total sample size. For the case of H0, we generated
data under the logistic models L3 or L4 (scenarios 1-5). For the
case of H1, we generated data under L3 (scenarios 6 and 7), L4
(scenarios 8-13) and neither (scenarios 14-16).
The scenarios under the parametric structures are shown in
Figure 3 (scenarios 1-13). For these parametric scenarios, the
parameter values are presented in Table 1. For scenarios 14 to
16, we broke the parametric structures, so both L3 and L4 are
misspecified models in the 3 scenarios. We made pointwise
assumptions p1 ¼ 0.2, p2 ¼ 0.09, p3 ¼ 0.1, p4 ¼ 0.2, p5 ¼
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0.4, and p6 ¼ 0.6 in scenario 14; 0.2, 0.09, 0.07, 0.2, 0.4, and
0.6 in scenario 15, respectively; and 0.2, 0.07, 0.08, 0.2, 0.4,
and 0.6 in scenario 16, respectively. Each scenario was simulated 1000 times, and 2000 bootstrap samples were used per
simulated sample. We fixed the significance level at a ¼ .05,
and the probability of rejecting H0 was recorded for each
method under each scenario.

Simulation Result
Table 2 provides the simulation results. When H0 was true in
scenarios 1 to 5, the L3 model violated a ¼ .05 in some scenarios at mild degree, and the L4 model violated a ¼ .05 at
serious degree in scenario 2. The estimated type I error probability was .082 which is difficult to believe that it just happened by chance for 1000 replications of the scenario. In each
scenario, the model averaging method MAP rejected H0 with a
probability between the resulting probabilities in L3 and L4
with an anticipated result. The model averaging method MASP
obeyed a ¼ .05 in the 5 null scenarios.
In scenarios 6 and 7, when H1 was true under the L3 model,
the L4 model led to slightly lower statistical powers than the L3
model due to overparameterization. The MAP model yielded
statistical power between the results in M3 and M4 as anticipated. On the other hand, the MASP yielded substantially lower
statistical powers in the 2 scenarios. When the true dose–
response curve is generated under the simple L3 model, the
L3 model outperformed which is not surprising.
In scenarios 8 to 13, when H1 was true under the L4 model,
the L3 model could not tolerate model misspecification by
showing substantially lower statistical powers due to the inflexibility. The L4 model mostly showed outperformance because
the scenarios belong to its own parameterization. In these 6
scenarios, the MASP model was consistently more powerful
than the MAp model despite the contribution of the true L4
model to MAP. In scenarios 9 to 11, the MASP model showed
comparable results to the results from the true L4 model.
We now turn our focus on scenarios 14, 15, and 16. Recall
that these 3 scenarios did not belong to any of L3, L4, MAP,
and MASP. The M3 model could not reject H0 even once, the
L4 model showed statistical powers of .180, .200, and .268,
respectively, and the MAP model showed statistical powers of
.107, .144, and .200, respectively. On the other hand, the
MASP showed statistical powers of .438, .580, and .666,
respectively.
The take-home message is clear. The parametric L3 and L4
models sometimes showed outperformance within their own
parameterizations (statistical power of .984 and .998 from L3
in scenarios 6 and 7, respectively; statistical power of .570,
.474, .706, .525, and .768 from L4 in scenarios 8, 9, 10, 12 and
13, respectively; see Table 2), but they performed poorly when
the truth was not under the model (statistical power of 0 from
L3 in scenarios 14, 15, and 16; statistical power of .180, .200,
and .268 from L4 in scenarios 14, 15, and 16 which are less
than one half when compared to .438, .580, and .666 from
MASP in the respective scenarios; see Table 2). This is a
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Figure 3. Simulation scenarios generated by the logistic models (scenarios 1-13). The parameter values are provided in Table 1.
Table 1. Parameter Values for Scenarios 1 to 13 Under the Logistic Model.
Scenario
b0
b1
b2
b3

1

2

3

4

5

6

7

8

9

10

11

12

13

1.3
0
0
0

1.3
0
1
1

1.3
0
3
1

1.3
0
1
.5

2.3
0
3
.5

1.39
7.33
14.66
1

1.39
10.02
20.04
1

1.39
5.18
7.33
.5

1.39
4.62
5.82
.33

1.39
7.09
10.02
.5

1.39
6.31
7.95
.33

1.39
7.33
14.66
.5

1.39
10.02
20.04
.5

general phenomenon in statistics. On the other hand, the MASP
model was relatively less sensitive, and the model averaging
among the semiparametric model (MASP) showed greater statistical power than the model averaging among the parametric
models (MAP) in the scenarios except when L3 was the true
model (see scenarios 8-16 in Table 2).

Application
In this section, we apply the 4 models (L3, L4, MAP, and
MASP) to some of binary data discussed in Calabrese and Baldwin14 and compare P values from the 4 models.

Calabrese and Baldwin14 discussed the effects of saccharin
on hyperplasia of the urinary bladder. The 6 experimental
doses were 0, .01, .1, 1, 5, and 7.5 (% in diets). The respective
observed proportions of tumor incidence were 10/73 (14%), 6/
71 (8%), 4/81 (5%), 4/76 (5%), 6/64 (9%), and 19/62 (31%)
for male rats (see the top left panel in Figure 4). When we
implemented the L3, L4, MAP, and MASP models, the respective P values were .042, .027, .034, and .059, respectively.
This is one of the cases when the parametric models adequately described the dose–response relationships, and the
MASP model could not achieve the significance level a ¼
.05. At the same experimental doses, the respective observed

6
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Table 2. Simulation Results, the Probability of Rejecting H0 Based on
1000 Simulated Data per Scenario.a
Scenario
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

True Model

L3

L4

MAP

MASP

L3/L4
L3/L4
L3/L4
L3/L4
L3/L4
L3
L3
L4
L4
L4
L4
L4
L4
–
–
–

.055
.056
.019
.066
.000
.984
.998
.277
.135
.387
.145
.318
.453
.000
.000
.000

.044
.082
.029
.038
.003
.764
.845
.570
.474
.706
.635
.525
.768
.180
.200
.268

.042
.061
.018
.043
.000
.894
.948
.467
.327
.641
.517
.446
.660
.107
.144
.200

.044
.037
.020
.025
.019
.279
.400
.474
.470
.673
.689
.475
.670
.438
.580
.666

a
L3 represents logistic regression model with the 3 parameters b0, b1, and b2;
L4, logistic regression model with the 4 parameters b0, b1, b2, and b3; MAP,
model averaging with the parametric models L3 and L4; MASP, model averaging
with the semiparametric models.

proportions of incidence were 3/85 (4%), 0/81 (0%), 0/81
(0%), 3/90 (3%), 5/88 (6%), and 10/76 (13%) for female rats
(see the top right panel in Figure 4). When we implemented
the L3, L4, MAP, and MASP models, the respective P values
were .811, .070, .207, and .014, respectively. As shown in the
figure (the top right panel), the data points in the observed
range are not symmetric, so the L3 model was not able to
model the observed nonmonotonic dose–response relationship adequately.
Calabrese and Baldwin14 also discussed the effect of 3Methylcholanthrene on pulmonary tumors in female rats.
The 9 experimental doses were 0, .005, .015, .046, .137,
.4, 1.2, 3.7, and 11.1 (mg). The observed proportions of tumor
incidence were 15/34 (44%), 1/18 (6%), 5/19 (26%), 7/18
(39%), 6/20 (30%), 12/24 (50%), 8/11 (73%), 10/10
(100%), and 11/11 (100%), respectively (see the bottom left
panel in Figure 4). Compared to the previous data set (effect
of saccharin on urinary bladder), it has a smaller total sample
size but a larger number of experimental doses. The L3, L4,
MAP, and MASP models yielded P values of .869, .070, .224,
and .003, respectively. As shown in Figure 4 (the bottom left
panel), the L3 model was not flexible enough to describe the
observed data, and the L4 model was quite flexible to follow
the observed nonmonotonic trend though it did not achieve
statistical significance. Under the MASP model, the data
served as significance evidence for hormesis with a P value
.003 < a ¼ .05.
As a final example, the same paper14 discussed the effect of
cadmium chloride on testicular tumors. From the 7 experimental doses 0, 1, 2.5, 5, 10, 20, and 40 (mmol/kg), the observed
proportions of incidence were 8/45 (17.8%), 1/30 (3.3%), 3/29
(10.3%), 3/30 (10.0%), 4/30 (13.3%), 21/29 (72.4%), and 24/29
(82.8%), respectively (see the bottom right panel in Figure 4).

Despite the strong hormetic trend, P values from L3, L4, MAP,
and MASP were .99, .64, .65, and .06, respectively, and they
seem to be influenced by the 2 data pints at the high doses 20
and 40 mmol/kg. The P values from the parametric methods
(L3, L4, and MAP) do not seem credible, and the P value from
averaging the semiparametric models seems more credible
based on the observed trend before modeling. In the figure
(the bottom right panel), the L3 model was not able to model
the asymmetric hormetic trend, and the flexibility of the L4
model was used to chase the 2 data points at the high experimental doses rather than the data points at low doses. An
interesting issue with the L4 model is discussed in the following section.

Discussion
The focus of this article is not to argue the existence of hormesis for a particular carcinogen. Our focus is a valid hypothesis
testing for a hormetic effect at low doses. We presented the
different characteristics of averaging parametric models and
averaging semiparametric models. In conclusion, when the true
hormetic relationship is under the simple L3 model, the parametric approach MAP (and individual L3 and L4) outperformed
the semiparametric approach MASP, which is not surprising.
On the other hand, when we compare the 2 averaging methods,
MASP outperformed MAP when the true hormetic relationship
is nonparametric and even when the truth is generated under the
parametric L4 model. It is also shown that the parametric
approaches cannot tolerate model misspecification for the
hypothesis testing. To this end, when the truth does not follow
a parametric form, MASP can be useful for more robust and
higher statistical power.
In large sample studies with many experimental doses in a
hormetic range, a nonparametric method can be a more reasonable approach because it can disconnect information between
doses inside a hormetic range and higher doses. May and Bigelow3 discussed the practical challenges due to insufficient sample sizes and a lack of experimental doses (missing a potential
hormetic range). In small sample studies, borrowing mathematical structure (ie, parametric models) to gain efficiency seems
inevitable. As discussed in “Results,” however, it sometimes
gives us a misleading result not simply due to a lack of evidence but due to model misspecification and high-leverage data
points (recall the low statistical power from L3, L4, and MAP in
scenarios 14-16 in Table 2). Motivated by this fact, we considered averaging semiparametric models (MASP) with AIC
weights to test for a hormetic effect at low doses. When we
implemented to real data, calculated P values from MASP made
more sense than P values from L3, L4, and MAP particularly in
the last applied example in “Application” (cadmium chloride
on testicular tumors).
In the simulation study, we showed pros and cons of the
parametric methods (L3, L4, and MAP) and of the semiparametric method (MASP). Under the correctly specified parametric form, the statistical power from L3 was highest
among the 4 methods as shown in scenarios 6 and 7 in Table
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Figure 4. Fitted dose–response curves under the L3 and L4 models using the maximum likelihood estimates.

2, and MAP outperformed MASP in the 2 scenarios generated
by L3. Under the wrong parametric form, we lost statistical
power substantially as shown in scenarios 14 to 16 (zero statistical power from L3 in Table 2). We observed that MASP
outperformed MSP in the 3 scenarios generated outside of L3 or
L4. Even when the true scenario was generated by L4, MASP
could yield higher statistical power than MAP as shown in
scenarios 8 to 13 (see Table 2). In practice, we cannot guarantee that observed outcomes (which are based on the unknown
true dose–response relationship) will follow a parametric
model as seen in the cadmium chloride data, and it is not under
our control. Instead, the proposed model averaging method
with semiparametric models does not require the parametric
form, and we learned that it is relatively less sensitive to the
shape of observed dose–response trend.
For the L4 model, we refitted the cadmium chloride data
with the restriction 0 < b3 < 1. The restricted parameterization
yielded a P value lower than a ¼ .05 by adequately modeling
the asymmetric hormetic zone. However, when we ran a simulation study under the null scenarios, it violated the significance

level a ¼ .05 seriously. In other words, the restricted parameterization tended to favor H1 too often when H0 is true. Additionally, we implemented the nonparametric regression method
discussed in Hall and Heckman20 in the simulation study. The
advantage of a nonparametric method is insensitivity to data
points at high doses, but it yielded lower statistical powers than
MASP in all of the alternative scenarios (generally below .2).
We also studied other methods among others. We modified the
test statistic in Baraud et al,21 which is more appropriate for the
binomial data (ie, difference in the 2 probabilities, comparing
the control group and the lowest nonzero dose group). It tended
to be too conservative, and it did not seem appropriate for a
sparse experimental doses. Similarly, we tested an umbrella
shape at low doses (decreasing then increasing) using the additive constrained regression.22 Due to the small number of dose
groups, the model fitted the data exactly, and it inflated the type
I error rate in null scenarios. A nonparametric method is often
useful for a large sample study, but 50 experimental units per
dose group with 6 experimental units do not seem sufficiently
large particularly for binary outcomes.
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To further study L3, L4, MAP, and MASP for increased
sample sizes (fixing the experimental doses), we manipulated the cadmium chloride data by doubling the sample size
while maintaining the observed proportions, that is 16/90
(17.8%), 2/60 (3.3%), 6/58 (10.3%), 6/60 (10.0%), 8/60
(13.3%), 42/58 (72.4%), and 48/58 (82.8%). Recall the P
values were .99, .64, .65, and .06 for L3, L4, MAP, and
MASP, respectively, before the manipulation (see Application). After the manipulation, the P values changed to .999,
.727, .727, and .006 for L3, L4, MAP, and MASP, respectively. When we multiplied the sample size by 10, that is
80/450 (17.8%), 10/300 (3.3%), 30/290 (10.3%), 30/300
(10.0%), 40/300 (13.3%), 210/290 (72.4%), and 240/290
(82.8%), the P values were close to 1, .943, .943, and close
to 0 for L3, L4, MAP, and MASP, respectively. Then, we
tested an additional simulation scenario under the assumptions (1) p1 ¼ .178, p2 ¼ .033, p3 ¼ .103, p4 ¼ .100, p5 ¼
.133, p6 ¼ .724, and p7 ¼ .828 and (2) n1 ¼ 450, n2 ¼ 300,
n3 ¼ 290, n4 ¼ 300, n5 ¼ 300, n6 ¼ 290, and n7 ¼ 290. The
resulting statistical powers were near 0, .005, .005, and near
1 for L3, L4, MAP, and MASP, respectively. The results
illustrate the impact of model misspecification even with
large data under the parametric methods when we test for
hormesis.
The Generic Hockey Stick model proposed by Bogen6 is a
parametric model with the enhanced polynomial flexibility
and the link function used in the linearized multistage
model.23 In sparse data, it may have the advantage of utilizing
3 parameters to allow greater flexibility than the L3 models
considered in this study. However, the Fisher expected information tells us that the parameter estimation still heavily
depends on high data points when we use a polynomial predictor. In practice, high-response data are removed when (1)
they are irrelevant to low-dose inference and (2) they severely
deviate from an assumed parametric model. We concern
about too few data points after removing the data points, and
it may increase the type I error rate under the null scenario. It
is our future study.
Based on the simulation study, we have thought that averaging L4 and MASP can balance the sensitivity (when the
observed data points can be approximated by the assumed
parametric structure) and the robustness (when they do not
follow the assumed parametric structure). It is our current
research direction.

Appendix
Model Averaging of L3 and L4
Let yij ¼ 1 if we observe the ith experimental unit treated by
dose xj showed a toxic outcome (and yij ¼ 0 otherwise) for
i ¼ 1, . . . , nj and j ¼ 1, . . . , J (see Model Averaging in
Parametric Models [L3 and L4] subsection). Let pj denote
the probability of observing a toxic event at dose xj which is
unknown for j ¼ 1, . . . , J. Given the data, the log-likelihood
function is
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l¼

nj 
J X

X
yij logðpj Þ þ ð1  yij Þlogð1  pj Þ
j¼1 i¼1

The L3 model assumes
2

pj ¼

eb0 þb1 xj þb2 xj

2

1 þ eb0 þb1 xj þb2 xj

so l is a function of b0, b1, and b2, denoted by lL3(b0, b1, b2).
The L4 model assumes
b3
þb

pj ¼

eb0 þb1 xj

b3

1 þ eb0 þb1 xj

2b3
2 xj
2b3

þb2 xj

so l is a function of b0, b1, b2, and b3, denoted by lL4(b0, b1,
b2, b3). Let ^l L3 denote the maximized lL3(b0, b1, b2) with
respect to (b0, b1, b2), and let ^l L4 denote the maximized
lL4(b0, b1, b2, b3) with respect to (b0, b1, b2, b3). The AIC of
the L3 model is defined as AICL3 ¼ 2^l L3 þ 2p ¼ 2^l L3 þ 6
because the model has p ¼ 3 parameters. The AIC of the L4
model is defined as AICL4 ¼ 2^l L4 þ 2p ¼ 2^l L3 þ 8 because
it has p ¼ 4 parameters. Then the AIC weight of the L3 model
and of the L4 model is
wL3 ¼

e0:5AICL3
;
þ e0:5AICL4

e0:5AICL3

wL4 ¼

e0:5AICL4
;
þ e0:5AICL4

e0:5AICL3

respectively.

Type I Error Rate Under MAP
Assume the null hypothesis H0 is true (see Model Averaging
in Parametric Models [L3 and L4] subsection). Let B denote
the number of bootstrap samples. Let w be a number between
0 and 1 (ie, AIC weight). Let p3 denote the proportion of
bootstrap estimates such that b^ 1 > 0 under the L3 model.
Consider a significance level a ¼ .05. In this case, under the
L3 model, we reject H0 in favor of H1 when B  p3 < .05  B.
Similarly, let p4 denote the proportion of bootstrap estimates
such that b^ 1 > 0 under the L4 model. Under the L4 model, we
reject H0 in favor of H1 when B  p4 < .05  B. Now, consider
a mixture bootstrap distribution of estimated b1 (ie, averaging
the 2 bootstrap distributions from L3 and L4). If L3 is
weighted by w and L4 is weighted by 1  w, we reject H0
in favor of H1 when B [w  p3 þ (1  w)  p4] < .05  B
under the model averaging MAP. Now let R3, R4, and RMA
denote the event that H0 is rejected under L3, L4, and MAP,
respectively. We consider the 4 cases. If R3 ∩ R4 occurs, it
implies RMA (case 1). If R3 ∩ RC4 occurs (ie, H0 is rejected
under L3 but not under L4), it is inconclusive (case 2). If
RC3 ∩ R4 occurs, it is inconclusive (case 3). If RC3 ∩ RC4 occurs,
it implies RCMA . To this end,
PðRMA Þ  PðR3 ∩ R4 Þ þ PðR3 ∩ RC4 Þ þ PðRC3 ∩ R4 Þ
¼ PðR3 Þ þ PðRC3 ∩ R4 Þ
and
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PðRMA Þ  PðR3 ∩ R4 Þ þ PðR3 ∩ RC4 Þ þ PðRC3 ∩ R4 Þ
¼ PðR4 Þ þ PðR3 ∩ RC4 Þ
In other words, the type I error rate under MAP has the upper
bound


PðRMA Þ  min PðR3 Þ þ PðRC3 ∩ R4 Þ; PðR4 Þ þ PðR3 ∩ RC4 Þ
If we observe an unusual original sample against H0, both
the probability of R3 and the probability of R4 increase, so
PðRC3 ∩ R4 Þ and PðR3 ∩ RC4 Þ are fairly small. To this end, the
type I error rate under MAP cannot be too far away from a range
between the type I error rate under L3 and under L4. In the
simulation study (“Simulation Result” and Table 2), we
observe that P(RMA) is close to the minimum of P(R3) and
P(R4) under the null scenarios (scenarios 1-5).

Model Averaging of M1, . . . , MJ2
Assuming model Mk, for k ¼ 1, . . . , J  2, the log-likelihood
function is given by (see Application of Model Averaging to
Semiparametric Models subsection)
lk ðp1 ; :::; pJ Þ ¼

nj 
J X
X

yij logðpj Þ þ ð1  yij Þlogð1  pj Þ



j¼1 i¼1

with the restriction p2 ¼ . . . ¼ pkþ1.
 For model M1, it is the saturated model, so the maximum
^l 1 can be achieved by letting pj ¼ Si yij/nj, the observed
proportion of toxic outcomes at dose xj.
 For model M2 with the restriction p2 ¼ p3, the maximum
^l 2 can be achieved by letting pj ¼ Si yij/nj for j not being
equal to 2 or 3 and p2 ¼ p3 ¼ (Si yi2 þ Si yi3)/(n2 þ n3)
which is the pooled estimation.
 For model M3, with the restriction p2 ¼ p3 ¼ p4, the
maximum ^l 3 can be achieved by letting pj ¼ Si yij/nj for j
not being equal to 2, 3, or 4 and p2 ¼ p3 ¼ p4 ¼ (Si yi2 þ
Si yi3 þ Si yi4)/(n2 þ n3 þ n4).
 This pattern continued up to MJ2, where J is the number of fixed experimental doses.
The AIC of model Mk is AICk ¼ 2^l k þ 2pk , where pk ¼ J
 k þ 1 is the number of free parameters in the model. Then the
AIC weight of Mk is given by
wk ¼

e0:5AIC1

e0:5AICk
þ . . . þ e0:5AICJ 2
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